BridgeBio Pharma, Inc. — Director's Dealing 2025

Nov 8, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2025-11-06

Reporting Person: DANIELS RONALD J (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-06	Common Stock	M	61031	$34.65	Acquired	78022	Direct
2025-11-06	Common Stock	S	61031	$63.7217	Disposed	16991	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-06	Stock Option (Right to Buy)	$34.65	M	61031	Disposed	2030-02-11	Common Stock (61031)	Direct

Footnotes

F1: Represents the weighted average sale price of the shares sold from $63.70 to $63.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

F2: The shares subject to this option vested and became exercisable in three annual installments from February 12, 2020 to February 12, 2023.